Aptevo Therapeutics Inc. filed a Form 8-K on November 5, 2026, announcing a clinical development milestone for its drug candidate mipletamig, specifically a substantial reduction in infusion-related reactions following refinements to its priming-dose regimen.

Key Highlights

  • Clinical milestone: Aptevo Therapeutics reported a substantial reduction in infusion-related reactions (IRRs) for mipletamig, according to the filing.
  • Cause attributed: The company disclosed the IRR reduction followed "successive refinements to its priming-dose regimen."
  • Announcement method: The milestone was communicated via a press release dated November 5, 2026, attached as Exhibit 99.1.
  • Signing officer: The filing was signed by Daphne Taylor, Senior Vice President and Chief Financial Officer.
  • Exchange listing: Aptevo Therapeutics common stock ($0.001 par value) trades on NASDAQ:APVO.

Aptevo Discloses Mipletamig Priming-Dose Regimen Improvements

Aptevo Therapeutics Inc. (NASDAQ:APVO) submitted a current report on November 5, 2026, under Item 8.01 (Other Events) of Form 8-K. According to the filing, the company issued a press release on that same date announcing what it described as "an important clinical development milestone" for mipletamig. The filing states the milestone centers on "a substantial reduction in infusion-related reactions (IRRs) following successive refinements to its priming-dose regimen."

The filing does not provide additional quantitative data regarding the degree of the IRR reduction, the patient population involved, or the specific nature of the priming-dose regimen changes within the body of the 8-K itself. The full details, according to the filing, are contained in the attached press release designated as Exhibit 99.1. The cover page interactive data file is included as Exhibit 104.

The report was signed on behalf of Aptevo Therapeutics by Daphne Taylor, identified in the filing as Senior Vice President and Chief Financial Officer. The company is incorporated in Delaware, maintains its principal executive offices at 2401 4th Avenue, Suite 1050, Seattle, Washington 98121, and carries Commission File Number 001-37746.

What Was Disclosed

Aptevo Therapeutics filed an 8-K on November 5, 2026, disclosing a clinical milestone for mipletamig: a substantial reduction in infusion-related reactions attributed to refinements in its priming-dose regimen, with details provided via an attached press release.